A Phase I Study of Safety, Pharmacokinetics, and Pharmacodynamics of Concurrent Everolimus and Buparlisib Treatment in Advanced Solid TumorsTaofeek K. Owonikoko, Fadlo R. Khuri, Colleen Lewis et al.|Clinical Cancer Research|2020Cited by 14
Abstract CT303: A phase I pharmacokinetic and pharmacodynamic evaluation of the combination of everolimus and buparlisib for concurrent mTOR and PI3K pathway blockade in patients with advanced solid tumorsTaofeek K. Owonikoko, Fadlo R. Khuri, R. Donald Harvey et al.|Cancer Research|2015Cited by 0